NAII

Business Context and Reporting Period

Company: Natural Alternatives International, Inc. (NAI)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2010 (First Quarter of Fiscal 2011)
Business Overview: NAI primarily provides private label contract manufacturing services for nutritional supplements and health care products. It also markets branded products under the "Pathway to Healing" line and holds patent rights for beta-alanine (CarnoSyn).

Key Financial Metrics

Note: All figures in thousands except per share data and percentages.

Material Changes vs. Prior Period

• Revenue Decline: Net sales decreased 21.3% year-over-year. Private label contract manufacturing sales dropped 21.4% due to lower volumes from two major customers (Mannatech and NSA International). Branded product sales declined 16.3% due to softening demand for the Pathway to Healing line.
• Profitability: Despite lower sales, gross margin improved by 1.4 percentage points to 20.0%, driven by a favorable shift in sales mix and lower material costs. Operating income fell 33.5% to $935,000.
• Cash Flow: Net cash provided by operating activities dropped significantly to $63,000 from $1.3 million in the prior year, primarily due to a $413,000 cash outflow from increased accounts receivable and a $1.6 million increase in inventory.
• Tax Impact: Income tax expense decreased 59.3% to $71,000. U.S. federal and state tax expenses were fully offset by the release of deferred tax asset valuation allowances using net operating loss carryforwards.
• Discontinued Operations: The legacy Real Health Laboratories (RHL) business was fully divested. There was no income from discontinued operations in Q1 2011, compared to $95,000 in Q1 2010.

Guidance, Outlook, and Risks

• Outlook: Management expects net sales and operating income for the second quarter of fiscal 2011 to be lower than the comparable prior year period due to uncertain economic conditions, reduced sales volumes, and lower pricing from major customers.
• Strategy: Focus remains on leveraging certified facilities for contract manufacturing, re-launching the Pathway to Healing product line with increased marketing, and commercializing the patent estate (CarnoSyn).
• Currency Risk: Results benefited from a strengthening Euro. Management notes that future results could be negatively affected if this favorable foreign exchange trend does not continue. The company has entered into forward contracts to hedge against Euro exchange risk.
• Liquidity: The company maintains $8.3 million in cash and a $7.5 million working capital line of credit with no outstanding borrowings. Management believes this is sufficient to fund operations for the next 12 months.
• Customer Concentration: Revenue concentration risk remains high. Two customers accounted for 71% of total net sales in Q1 2011 (down from 84% in Q1 2010).

Investor Verification Checklist

• Customer Dependency: Verify the stability of relationships with the top two customers (Mannatech and NSA International), which represent 71% of revenue.
• Inventory Levels: Review the $1.6 million increase in inventory and assess the risk of obsolescence or write-downs given the sales decline.
• Cash Flow Sustainability: Monitor the sharp decline in operating cash flow ($1.3M to $63K) and its impact on working capital management.
• Branded Product Recovery: Assess the effectiveness of the re-launch strategy for the Pathway to Healing product line to reverse the 16.3% sales decline.
• Foreign Exchange Exposure: Evaluate the impact of currency fluctuations on future margins, given the significant portion of sales outside the U.S. (36.5% of total sales).